Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the ...

UT Health San Antonio Multispecialty and Research Hospital is the first hospital in Texas to approve a non-narcotic ...

Xifyrm is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.

Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the debut of a powerful new ...

The Food and Drug Administration (FDA) has approved Xifyrm ™ (meloxicam injection) for use in adults for the management of moderate to severe pain, alone or in combination with non-NSAID ...

Zembrace ® SymTouch ® (sumatriptan succinate) injection (Zembrace) and Tosymra ® (sumatriptan) nasal spray are prescription ...

Findings highlight the advantages of Adolore’s approach for the delivery of proprietary gene therapy directly to specialized ...

UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to ...

Innocan has initiated regulatory submissions in support of advancing LPT-CBD into human clinical trials. This progress marks ...

US FDA approves Azurity Pharma’s Xifyrm for management of moderate-to-severe pain in adults: Woburn, Massachusetts Thursday, June 12, 2025, 12:00 Hrs [IST] Azurity Pharmaceutica ...